VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 336 filers reported holding VALEANT PHARMACEUTICALS INTL in Q4 2017. The put-call ratio across all filers is 1.53 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $8,134,000 | +46.0% | 350,000 | 0.0% | 0.13% | +42.9% |
| Q1 2018 | $5,572,000 | -82.1% | 350,000 | -76.7% | 0.09% | -87.2% |
| Q4 2017 | $31,170,000 | +0.7% | 1,500,000 | -30.6% | 0.71% | -3.1% |
| Q3 2017 | $30,953,000 | +8.4% | 2,160,000 | +30.9% | 0.74% | +44.9% |
| Q2 2017 | $28,545,000 | +293.2% | 1,650,000 | +230.0% | 0.51% | +202.4% |
| Q4 2016 | $7,260,000 | +253.1% | 500,000 | +5303.1% | 0.17% | +784.2% |
| Q2 2015 | $2,056,000 | -97.6% | 9,254 | -98.5% | 0.02% | -98.0% |
| Q4 2014 | $86,809,000 | +5.6% | 606,587 | -3.2% | 0.95% | +54.4% |
| Q3 2014 | $82,229,000 | +38.1% | 626,748 | +32.7% | 0.61% | +36.7% |
| Q2 2014 | $59,552,000 | +173.1% | 472,187 | +185.5% | 0.45% | +107.9% |
| Q1 2014 | $21,806,000 | – | 165,411 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chou Associates Management | 1,648,992 | $38,323,000 | 14.52% |
| Paulson & Co. | 20,839,035 | $484,299,000 | 9.89% |
| MILLER VALUE PARTNERS, LLC | 4,999,064 | $116,178,000 | 4.34% |
| GoldenTree Asset Management | 1,140,205 | $26,498,000 | 4.21% |
| Pomelo Capital LLC | 1,760,000 | $40,902,000 | 4.00% |
| Bruce & Co., Inc. | 860,000 | $19,986,000 | 3.98% |
| ValueAct Holdings | 18,033,149 | $419,090,000 | 3.79% |
| Stanley Capital Management, LLC | 318,400 | $7,400,000 | 3.25% |
| Kazazian Asset Management, LLC | 134,784 | $3,132,000 | 2.87% |
| Phoenix Investment Adviser LLC | 58,400 | $1,357,000 | 2.48% |